NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at UBS Group AG from $18.00 to $22.00. They now have a "buy" rating on the stock.
NeuroPace (NASDAQ:NPCE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.
NeuroPace (NASDAQ:NPCE) had its "buy" rating reaffirmed by analysts at UBS Group AG.